Participant experiences and recommendations for psychedelic clinical trials and future treatment delivery: a qualitative study with experts by experience from the Psychedelic Participant Advocacy Network.
Frontiers in psychiatry · 2026
Abstract e pubblicazione originale
L’abstract è consultabile nella fonte originale. Non viene ripubblicato qui perché non risulta verificata una licenza compatibile.
Leggi nella fonte originale ↗Parole chiave
DMTclinical trialsdrug approval pathwayseating disordersmajor depressive disorderparticipant perspectivespsilocybinpsychedelicsClinical TrialsEating DisordersMajor Depressive DisorderPsilocybinDmtPsychedelicsParticipant PerspectivesDrug Approval Pathways
Come citare questo studio
Seynaeve M, Schneider L, Roullier I, Lazenby K, Lilley C, Lobo S, Ermakova AO, Wells H, Cleare A, Rucker J. (2026). Participant experiences and recommendations for psychedelic clinical trials and future treatment delivery: a qualitative study with experts by experience from the Psychedelic Participant Advocacy Network.. Frontiers in psychiatry. DOI: 10.3389/fpsyt.2026.1682810
Consulta la pubblicazione originale ↗